Trial Profile
ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALTTO
- Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 01 Feb 2024 Results of sub analysis assessing whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer, published in the Breast Cancer Research and Treatment
- 13 Sep 2022 Results identifying biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab, presented at the 47th European Society for Medical Oncology Congress.
- 01 Sep 2022 Results of sub analysis (n=2821 ) exploring the long-term outcomes of patients with small node-negative tumours published in the British Journal of Cancer.